Skip to main content

Table 1 Effect of 6-OHDA-lesion and STN-HFS on bilateral changes of optical density measurements of immunoreactive signals for VGLUT1-3

From: High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson’s disease

 

VGLUT1

VGLUT2

VGLUT3

 

Ipsilateral side

Controlateral side

Ipsilateral side

Controlateral side

Ipsilateral side

Controlateral side

A

Controls

6-OHDA

Controls

6-OHDA

Controls

6-OHDA

Controls

6-OHDA

Controls

6-OHDA

Controls

6-OHDA

CPu

51,35 (±3,2)

53,33 (±1,9)

48,78 (±3,4)

52,59(±1,7)

20,15 (±2,38)

12,64*(±1,5) -37%

19,76 (±2,3)

13,38*(±0,6) -33%

16, 65(±0,8)

18,15 (±1,7)

15,37 (±0,8)

16, 33 (±3,1)

PM Cx

55,54 (±3,3)

48,3 (±2,1)

55,81 (±2,9)

48,07 (±2,8)

18,56 (±1,7)

10,93*(±0,6) -42%

18,5 (±2,1)

11,12*(±0,6) -40%

14,34 (±0,9)

13,09 (±2,4)

14,39 (±0,9)

13, 02 (±2,5)

SS Cx

45,93 (±3)

35,37 (±1,6)

45,93 (±1,6)

38,93 (±1,6)

15,79 (±1,81)

9,22*(±0,4) -42%

16,44 (±1,8)

10,57*(±0,6) -36%

12,01 (±0,6)

10,28 (±2,1)

12,89 (±0,7)

11,63 (±2,4)

Acb

54,15 (±2,8)

63,43 (±2,8)

51,52 (±3,6)

59,65 (±3,1)

22,55 (±2,7)

13,56*(±2,1) -40%

22,14 (±2,6)

13,91*(±2,1) -47%

18,84 (±0,9)

23,33 (±1,1)

19,04 (±1,1)

23 (±1,2)

Thalamus

41,18 (±3,4)

34,15 (±1,7)

41,86 (±3,3)

32,47 (±1,1)

16,83 (±2,3)

8,85*(±0,4) -48%

17,49 (±2,4)

9,05*(±0,7) -48%

11,38 (±0,5)

9,85 (±1,3)

11,43 (±0,5)

9,79 (±1,1)

STN

21,13 (±2,7)

23, 56 (±4,6)

19,25 (±2,5)

20,65 (±4,2)

16,83 (±2,1)

7,66*(±1,3) -55%

15,53 (±2,3)

9,32*(±0,5) -40%

ND

ND

ND

ND

GP

ND

ND

ND

ND

12,78 (±1,9)

7,97(±1)

13,39 (±1,7)

8,83 (±1,1)

ND

ND

ND

ND

SNr

ND

ND

ND

ND

51,1 (±2,4)

11,26*(±0,3) -25%

15,76 (±2,2)

11,39*(±0,5) -28%

ND

ND

ND

ND

 

Ipsilateral side

Controlateral side

Ipsilateral side

Controlateral side

Ipsilateral side

Controlateral side

B

6-OHDA

6-OHDA + STN-HFS

6-OHDA

6-OHDA + STN-HFS

6-OHDA

6-OHDA + STN-HFS

6-OHDA

6-OHDA + STN-HFS

6-OHDA

6-OHDA + STN-HFS

6-OHDA

6-OHDA + STN-HFS

CPu

53,33 (±1,8)

65,07*(±3,4) +22%

52,59 (±1,7)

64,43(±3,2) +23%

12,64 (±1,5)

17,81*(±1,4) +41%

13,38 (±0,6)

17,61*(±1,8) +32%

18,15 (±1,7)

26,13*(±2,9) +44%

16,33 (±3,1)

24,88*(±1,8) +53%

PM Cx

48,3 (±2,2)

63,08*(±3,3) +31%

48,07 (±2,8)

64, 79*(±3,5) +35%

10,93 (±0,6)

16,93*(±1,6) +55%

11,12 (±0,6)

16,86*(±1,8) +52%

13,09 (±2,4)

20*(±1,9) +53%

13,02 (±2,5)

16,62*(±1,7) +51%

SS Cx

35,75 (±1)

54,25*(±3,8) +52%

38,93 (±1,6)

55,08*(±3,8) +41%

9,22 (±0,4)

14,03*(±1,4) +52%

10,57 (±0,6)

13,38*(±1,6) +27%

10,28 (±2,1)

20,44*(±2,1) +99%

11,63 (±2,4)

16,78*(±1,4) +44%

Acb

63,43 (±2,8)

65,39 (±3,9)

59,65 (±4,1)

65,06 (±4,1)

13,56 (±2,1)

20,25*(±1,3) +49%

13,91 (±2,1)

18,78*(±1,2) +35%

23,23 (±1,1)

31,7* (1,2) +36%

23 (±1,2)

31,89*(±1,2) +38%

Thalamus

34,15 (±1,7)

48,1*(±3,8) +41%

32,47(±1,1)

46,37 (±3,6) +43%

8,85 (±0,4)

14,63*(±1,6) +65%

9,05 (±0,7)

13,5*(±1,5) +449%

9,85 (±1,3)

20,3*(±1,6) +106%

9,79 (±1,1)

19,38*(±2,5) +98%

STN

23,56 (±4,6)

17,78 (±2,6)

20,65 (±4,2)

19,34 (±3)

7,66 (±1,3)

14,79*(±1,5) +93%

9,32 (±0,5)

15,94*(±1,9) +71%

ND

ND

ND

ND

GP

ND

ND

ND

ND

7.97 (±1)

10,18 (±0,9)

8,83 (±1,1)

9,61 (±1)

ND

ND

ND

ND

SNr

ND

ND

ND

ND

11,26 (±0,3)

15,84*(±1,3) +41%

11,39 (±0,5)

16,64*(±1,4) +46%

ND

ND

ND

ND

  1. A, Modifications of VGLUT1-3 expression induced by unilateral 6-OHDA-lesion of SNc (control rats, n = 9; 6-OHDA rats, n = 6). *p<0.05, vs control group.
  2. B, Modifications of VGLUT1-3 expression induced by unilateral STN-HFS in 6-OHDA lesioned rats (6-OHDA rats, n = 6; 6-OHDA rats + STN-HFS, n = 10). *p<0.05, vs non stimulated 6-OHDA-lesioned group. Values of optical densities measurements are expressed as a mean ± standard error (SEM). Data were analyzed for each brain structure by Kruskal-Wallis tests with SigmaStat 3.1 software. Post-hoc analyses were carried out with the Dunn’s method. Bold numbers correspond to significant differences. Ipsilateral side: related to the lesion and/or stimulation side; Controlateral side: related to the lesion and/or stimulation side; Acb, Accumbens nucleus; CPu, Caudate Putamen (striatum); GP, Globus Pallidus; PM Cx, Premotor Cortex; SNr, Substantia nigra pars reticulata; SS Cx, Somatosensory Cortex; STN, Subthalamic nucleus; Thalamus (VL/VM).